NL-OMON54892尚未招募不适用
PRospective tumor sampling in oncology patients with solid tumors treated with Immune Modulating Agents - PRIMA
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Histological or cytological proven solid tumor
- •Age >=18 years
- •Written informed consent
- •Performance score: WHO 0-2 at the time of study entry
- •Planned treatment with (intravenous) immune modulating agents for any type of
- •cancer according to standard of care.
排除标准
- •Unable to draw blood for study purposes (e.g. severe anemia Hb <5,5 mmol/L)
- •Unable to safely obtain tumor biopsies
- •Known human immunodeficiency virus (HIV), chronic hepatitis B or C infection
研究者
相似试验
招募中
不适用
Blood sampling of oncology patients treated with monoclonal antibodiesAll malignancies that are treated with intravenous monoclonal antibodiesNL-OMON27631Erasmus Medical Center1,000
招募中
不适用
Prospective sampling in intravenously treated oncology patients: Monoclonal AntiBodiesmalignancy10027655cancerNL-OMON53070Erasmus MC, Universitair Medisch Centrum Rotterdam2,750
已完成
不适用
Protocol to obtain tumor biopsies from patients with locally advanced (incurable) or metastatic cancer to improve selection for clinical trials.metastatic cancermetastatic malignancy10027476NL-OMON40487niversitair Medisch Centrum Utrecht1,500
招募中
不适用
Prospective observational study molecular tumor board of the Comprehensive Cancer Center Mainfranken of the University Hospital of WürzburgC00-C97Malignant neoplasmsDRKS00029051niversitätsklinikum Würzburg998
已完成
不适用
An exploratory tumor biopsy-driven study to understand the relationship between biomarkers and indicators of clinical response in immunomodulatory treatment naïve unresectable stage III/IV melanoma patients receiving REGN2810 (anti-PD-1)melanomaskin cancerNL-OMON49259Regeneron Pharmaceuticals, Inc.8